Facial acneiform rash associated with sorafenib

Dermatology Online Journal

Volumn 15, Issue 4, 2009, Pages

  Fleta Asín, Beatriz ^a   Vañó Galván, Sergio ^a   Ledo Rodríguez, Alejandro ^b   Truchuelo Díez, Maite ^a   Jaén Olasolo, Pedro ^a  

^a King Abdullah Medical City   (Saudi Arabia)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TUMOR PROTEIN;

ACNE; ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; FACE RASH; FEMALE; HEMANGIOENDOTHELIOMA; HUMAN; PAPULE; PUSTULE; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FATALITY; LIVER TRANSPLANTATION; LIVER TUMOR; POSTOPERATIVE COMPLICATION; SKIN DISEASE; TUMOR RECURRENCE;

ACNEIFORM ERUPTIONS; ADULT; ANTINEOPLASTIC AGENTS; FACIAL DERMATOSES; FATAL OUTCOME; FEMALE; HEMANGIOENDOTHELIOMA, EPITHELIOID; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 66249098525     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Zureikat AH, McKee MD. Targeted therapy for solid tumors: current status. Surg Oncol Clin N Am. 2008 Apr;17(2):279-301, vii-viii. [PubMed]
2. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007 Dec;7(4):127-34. [PubMed]
3. U.S. Food and drug administration. Drug information. Nov 20, 2007; April 4, 2009. FDA Approves Sorafenib (Nexavar) for the Treatment of Unresectable Hepatocellular Carcinoma. FDA, Rockville, Maryland. Available in: http://www.fda.gov/CDER/Offices/OODP/whatsnew/sorafenib.htm
4. U.S. Food and drug administration. Drug information. January 26, 2006; April 4, 2009 FDA Approves New Treatment for Gastrointestinal and Kidney Cancer. FDA, Rockville, Maryland. Available in: http://www.fda.gov/bbs/topics/news/ 2006/new01302.html
5. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008 Mar;158(3):592-6. [PubMed]
6. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13 1001-11. [PubMed]
7. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol. 2007 Jan;32(1):71-4. [PubMed]
8. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005 Jul;6(7):491-500. [PubMed]
9. Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières D, Saltz L, Leyden J. Oncologist 2005 May;10(5):345-56. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. [PubMed]
10. Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007 Dec;12(12):1443-55. [PubMed]
11. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol. 2005 Oct;16(10):1688-94. 8. [PubMed]
12. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007 Mar;43(5):845-51. [PubMed]
13. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, Guillot B. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004 Jul;151(1):238-41. [PubMed]